Biotech and specialty health care stocks can be attractive speculations because product innovation can drive explosive growth and attract intense takeover interest from large pharmaceutical companies. The challenge is determining which ones justify the risk, because early-stage drug developers are numerous, and many remain cash-burning for years.
Even the few winners still face challenges such as adoption, scaling, and disruption, alongside the dreaded patent cliff. For drug developers, patent cliffs effectively limit the period of market exclusivity, making investor timing an equally critical factor in the investment thesis.
